Oncology Drug Advisory Committee

TG THERAPEUTICS, INC. (NASDAQ: TGTX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against TG Therapeutics, Inc. (NASDAQ: TGTX)

Retrieved on: 
Tuesday, September 6, 2022
Patient, BLA, NDA, Securities Exchange Act of 1934, TG, Survival, District court, Regulation of tobacco by the U.S. Food and Drug Administration, Therapy, Follicular lymphoma, NASDAQ, Lists of schools in England, Oncology Drug Advisory Committee, Death, Multiple sclerosis, Chronic lymphocytic leukemia, New Drug Application, Overalls, Food, Advertising, Court, CLL, Investment, NEW, GLOBE, Company, FDA, Labour government, News, The Legal 500, ODAC, Adult, Biologics license application, Lists of action films, SLL, Risk, Shanda, Prescription Drug User Fee Act, Review, Tobacco, Pharmaceutical industry, High-performance plastics, Medical device, Umbralisib, Ublituximab, U2

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (NASDAQ: TGTX) between January 15, 2020 and May 31, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934.
  • If you purchased TG Therapeutics securities, and/or would like to discuss your legal rights and options please visit TG Therapeutics, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

TGTX 10-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages TG Therapeutics (TGTX) Investors with Losses to Contact Firm’s Attorneys Before Sept. 16th Deadline in Securities Fraud Class Action

Retrieved on: 
Tuesday, September 6, 2022
Person, Steve Berman (lawyer), BLA, RMS, NDA, Safety, TG, Program, Follicular lymphoma, Therapy, Oncology Drug Advisory Committee, Multiple sclerosis, Chronic lymphocytic leukemia, SEC, CLL, Lymphocytosis, FDA, News, Fraud, Clinical trial, Review, Patient, Pharmaceutical industry, Umbralisib, Ublituximab

Then, on April 15, 2022 TG announced it withdrew its U2 BLA/U2sNDA based on safety data.

Key Points: 
  • Then, on April 15, 2022 TG announced it withdrew its U2 BLA/U2sNDA based on safety data.
  • Finally, on June 1, 2022 the FDA announced that it revoked approval for Umbralisib for treating MZL and FL due to safety concerns.
  • Were focused on investors losses and whether TG misrepresented safety data in connection with its submissions to the FDA, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in TG Therapeutics and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in TG Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – TGTX

Retrieved on: 
Tuesday, September 6, 2022
Ext, Lists of action films, NDA, BLA, Securities Exchange Act of 1934, TG, SEC Rule 10b-5, Survival, Degenerative disease, District court, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Follicular lymphoma, NASDAQ, LLP, Lists of schools in England, Oncology Drug Advisory Committee, Death, Multiple sclerosis, Chronic lymphocytic leukemia, Person, New Drug Application, Overalls, Food, Court, CLL, Lymphocytosis, Complaint, Lymphoid leukemia, GLOBE, Company, FDA, News, ODAC, Adult, Biologics license application, SLL, Pomerantz, Risk, Shanda, Prescription Drug User Fee Act, Acquisition, Review, Patient, Medical device, Pharmaceutical industry, High-performance plastics, Umbralisib, Ublituximab, U2

To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.

Key Points: 
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • TG Therapeutics, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Y-mAbs Announces Scheduling of FDA Advisory Committee Meeting for Omburtamab

Retrieved on: 
Thursday, September 1, 2022
COVID-19, BLA, Cancer, Research, CNS, Regulation of tobacco by the U.S. Food and Drug Administration, Therapy, Government, Oncology Drug Advisory Committee, Advisory Committee, Risk, Interim, Memorial Sloan Kettering Cancer Center, Private Securities Litigation Reform Act, Food, SEC, Â, GLOBE, FDA, Company, Tobacco Products Scientific Advisory Committee, GD2, Failure, Neoplasm, Annual report, Industry, Growth, MSK, Review, Marketing, Patient, Pharmaceutical industry

We look forward to the October 28, 2022 meeting with the Advisory Committee, as well as to continuing our dialogue with the FDA about OMBLASTYS and the important data, which we believe supports approval, said Thomas Gad, President, and Interim Chief Executive Officer.

Key Points: 
  • We look forward to the October 28, 2022 meeting with the Advisory Committee, as well as to continuing our dialogue with the FDA about OMBLASTYS and the important data, which we believe supports approval, said Thomas Gad, President, and Interim Chief Executive Officer.
  • This is another key step towards providing a potential treatment for pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma.
  • Researchers at Memorial Sloan Kettering Cancer Center (MSK) developed omburtamab, which is exclusively licensed by MSK to Y-mAbs.
  • In addition to conventional antibodies, the Companys technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in TG Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – TGTX

Retrieved on: 
Tuesday, August 30, 2022
Ext, Lists of action films, NDA, BLA, Securities Exchange Act of 1934, TG, SEC Rule 10b-5, Survival, Degenerative disease, District court, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Follicular lymphoma, NASDAQ, LLP, Lists of schools in England, Oncology Drug Advisory Committee, Death, Multiple sclerosis, Chronic lymphocytic leukemia, Person, New Drug Application, Overalls, Food, Court, CLL, Lymphocytosis, Complaint, Lymphoid leukemia, GLOBE, Company, FDA, News, ODAC, Adult, Biologics license application, SLL, Pomerantz, Risk, Shanda, Prescription Drug User Fee Act, Acquisition, Review, Patient, Medical device, Pharmaceutical industry, High-performance plastics, Umbralisib, Ublituximab, U2

To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.

Key Points: 
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • TG Therapeutics, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

TG THERAPEUTICS, INC. (NASDAQ: TGTX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against TG Therapeutics, Inc. (NASDAQ: TGTX)

Retrieved on: 
Tuesday, August 30, 2022
Patient, BLA, NDA, Securities Exchange Act of 1934, TG, Survival, District court, Regulation of tobacco by the U.S. Food and Drug Administration, Therapy, Follicular lymphoma, NASDAQ, Lists of schools in England, Oncology Drug Advisory Committee, Death, Multiple sclerosis, Chronic lymphocytic leukemia, New Drug Application, Overalls, Food, Advertising, Court, CLL, Investment, NEW, GLOBE, Company, FDA, Labour government, News, The Legal 500, ODAC, Adult, Biologics license application, Lists of action films, SLL, Risk, Shanda, Prescription Drug User Fee Act, Review, Tobacco, Pharmaceutical industry, High-performance plastics, Medical device, Umbralisib, Ublituximab, U2

NEW YORK, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (NASDAQ: TGTX) between January 15, 2020 and May 31, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934.
  • If you purchased TG Therapeutics securities, and/or would like to discuss your legal rights and options please visit TG Therapeutics, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

TGTX INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Encourages TG Therapeutics (TGTX) Investors with Losses to Contact Firm’s Attorneys, Deadline Approaching in Securities Fraud Class Action

Retrieved on: 
Monday, August 29, 2022
Person, Steve Berman (lawyer), BLA, RMS, NDA, Safety, TG, Program, Therapy, Follicular lymphoma, NASDAQ, SAN, Oncology Drug Advisory Committee, Multiple sclerosis, Chronic lymphocytic leukemia, SEC, CLL, Lymphocytosis, GLOBE, FDA, News, Fraud, Clinical trial, Review, Patient, Pharmaceutical industry, Umbralisib, Ublituximab

SAN FRANCISCO, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges TG Therapeutics, Inc. (NASDAQ: TGTX) investors who suffered significant losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges TG Therapeutics, Inc. (NASDAQ: TGTX) investors who suffered significant losses to submit your losses now .
  • A securities fraud class action has been filed.
  • Then, on April 15, 2022 TG announced it withdrew its U2 BLA/U2sNDA based on safety data.
  • If you invested in TG Therapeutics and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .

Vial Welcomes Dr. Brian Rini of the Vanderbilt-Ingram Cancer Center (VICC) to their Oncology CRO Advisory Board

Retrieved on: 
Sunday, August 28, 2022
Technology, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Ophthalmology, SAN, Solution, Oncology Drug Advisory Committee, Food, Clinical trial, Kidney cancer, Multimedia, MD, FDA, Cras, DOD, Vial, Knowledge, Dermatology, Vanderbilt, Vanderbilt University, Industry, Drug development, Patient, CRO, Pharmaceutical industry, Fine chemical, Medicine, Oncology

Rini will join Vial's Oncology CRO Advisory Board as a scientific advisor.

Key Points: 
  • Rini will join Vial's Oncology CRO Advisory Board as a scientific advisor.
  • On joining Vial's Oncology CRO Advisory Board, Dr. Rini shares, "I have devoted my career in Oncology and kidney cancer research to making an impact in patients' lives.
  • Dr. Rini brings a wealth of knowledge to Vial's Oncology CRO Advisory Board and will serve alongside members Dr. Arati Rao , Dr. Antoni Ribas , and Dr. Guru Sonpavde .
  • Vial operates across multiple Therapeutic Areas ( Dermatology CRO , Ophthalmology CRO , Oncology CRO , and Gastroenterology CRO ).

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in TG Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – TGTX

Retrieved on: 
Wednesday, August 24, 2022
Ext, Lists of action films, NDA, BLA, Securities Exchange Act of 1934, TG, SEC Rule 10b-5, Survival, Degenerative disease, District court, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Follicular lymphoma, NASDAQ, LLP, Lists of schools in England, Oncology Drug Advisory Committee, Death, Multiple sclerosis, Chronic lymphocytic leukemia, Person, New Drug Application, Overalls, Food, Court, CLL, Complaint, Lymphoid leukemia, GLOBE, Company, FDA, News, ODAC, Adult, Biologics license application, SLL, Pomerantz, Risk, Shanda, Prescription Drug User Fee Act, Acquisition, Review, Patient, Medical device, Pharmaceutical industry, High-performance plastics, Umbralisib, Ublituximab, U2

To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.

Key Points: 
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • TG Therapeutics, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

TGTX DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages TG Therapeutics (TGTX) Investors with Losses to Contact Firm’s Attorneys, Securities Fraud Lawsuit Pending

Retrieved on: 
Monday, August 22, 2022
Person, Steve Berman (lawyer), BLA, RMS, NDA, Safety, TG, Program, Therapy, Follicular lymphoma, NASDAQ, SAN, Oncology Drug Advisory Committee, Multiple sclerosis, Chronic lymphocytic leukemia, SEC, CLL, Lymphocytosis, GLOBE, FDA, News, Fraud, Clinical trial, Review, Patient, Pharmaceutical industry, Umbralisib, Ublituximab

SAN FRANCISCO, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges TG Therapeutics, Inc. (NASDAQ: TGTX) investors who suffered significant losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges TG Therapeutics, Inc. (NASDAQ: TGTX) investors who suffered significant losses to submit your losses now .
  • Then, on April 15, 2022 TG announced it withdrew its U2 BLA/U2sNDA based on safety data.
  • Were focused on investors losses and whether TG misrepresented safety data in connection with its submissions to the FDA, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in TG Therapeutics and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .